

Alison M. Bendele

DVM, PhD, DACVP

inotiv
analyze. answer. advance.



Distinguished Pathologist

alison.bendele@inotiv.com

ABOUT

Dr. Alison Bendele joined Inotiv in 2021 when it acquired Bolder BioPATH Inc, a CRO that she founded in 1998.

Dr. Bendele has published extensively on animal models of osteo and rheumatoid arthritis with a focus on the evaluation of potential therapeutic agents. She is a recognized expert in arthritis and joint evaluations, leading Inotiv's regulatory and investigative pathology in this area.

Before joining Inotiv's team, Dr. Bendele was at Eli Lilly, serving for nearly a decade as a pathologist specializing in discovery research and safety evaluation followed by 5 years at Amgen Boulder as director of preclinical pharmacology. She then founded and worked for Bolder BioPATH, a CRO.

Dr. Bendele earned her DVM at Texas A&M, then completed her residency training and Ph.D. in veterinary anatomic pathology at Purdue University.



AREAS OF EXPERTISE

- Toxicologic pathology on joints
- Osteoarthritis and rheumatoid arthritis disease models

MY JAM

- Horseback riding in reining competitions

